Karyopharm Therapeutics Inc. — FY 2014 Form 10-K
Reporting period: Year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Karyopharm is a clinical-stage drug developer; it had no revenue from product sales.
Business context and development
The company’s lead candidate, oral selinexor (KPT-330), inhibits XPO1 and was being studied in cancer. In 2014, Karyopharm initiated registration-directed trials in older patients with relapsed or refractory AML, Richter’s transformation, and third-line-or-later DLBCL. Other programs included solid-tumor studies, verdinexor for canine lymphoma, and preclinical or planned work in wound healing, viral disease, inflammation, and PAK4 inhibition. No candidate had marketing approval.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Contract and grant revenue | $0.229 million | $0.387 million |
| Research and development expense | $60.127 million | $28.452 million |
| General and administrative expense | $15.948 million | $5.885 million |
| Operating loss | $75.846 million | $33.950 million |
| Net loss | $75.777 million | $33.947 million |
| Net loss per share | $2.43 | $5.59 |
| Net cash used in operating activities | $51.447 million | $30.290 million |
FY 2014 R&D expense more than doubled, primarily from increased clinical-trial, manufacturing, personnel, consulting, and preclinical costs. G&A also rose substantially, including personnel, stock-based compensation, professional fees, and public-company costs. The company recorded $14.240 million of stock-based compensation versus $3.785 million in 2013. Revenue was immaterial relative to expenses; operating or gross margins are not informative for this pre-commercial business.
At December 31, 2014, cash and cash equivalents were $150.609 million, short-term investments $55.115 million, and long-term investments $8.658 million. Working capital was $195.450 million; total assets were $220.337 million and total liabilities $13.543 million. The balance sheet reports no borrowings. Operating cash use was partly offset by $112.837 million in net proceeds from the July 2014 share offering. Investing cash use was $67.031 million, primarily purchases of investments and property and equipment. The company reported $10.321 million of future minimum operating-lease payments.
After year-end, a January 2015 share offering generated approximately $90.9 million net. The filing gives differing runway statements: MD&A says existing funds would support the operating plan into 2018, while a financial-statement note says cash, investments, and January offering proceeds would fund the current plan through at least January 1, 2016.
Fourth-quarter results and changes
Unaudited Q4 2014 revenue was $16,000, operating expenses $25.958 million, operating loss $25.942 million, and net loss $25.928 million, or $0.79 per share. Compared with Q3 2014, net loss increased from $19.724 million to $25.928 million as quarterly operating expenses rose from $19.765 million to $25.958 million. Annual net loss increased from $33.947 million in 2013 to $75.777 million in 2014, reflecting expanded development activity and higher operating costs.
Outlook, risks, and notable items
- Management expected substantial increases in R&D and operating costs as trials advanced. It anticipated selinexor data from solid-tumor studies during 2015 and planned additional trials, including a possible myeloma study; these are forward-looking plans, not assured outcomes.
- The company said a potential selinexor launch in North America and Western Europe could occur as early as the second half of 2017, contingent on successful trials and regulatory approvals.
- Clinical evidence cited for selinexor was preliminary and interim, unaudited, and based on physician reports. The filing cautions that early responses may not predict later-stage success. Reported risks included gastrointestinal effects, fatigue, thrombocytopenia, neutropenia, and a potential for worsening pre-existing cataracts.
- Karyopharm depends on selinexor, has no product-sales revenue, and expects continuing losses and a need for additional capital. Clinical, regulatory, manufacturing, enrollment, intellectual-property, competition, reimbursement, and commercialization risks are material. Drug supply relied on third parties, with no long-term supply agreement or redundant supply arrangement reported.
- The company had no material legal proceedings and reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Reconcile the conflicting cash-runway disclosures (into 2018 versus through at least January 1, 2016), including the effect of the January 2015 offering and planned trial spending.
- Track cash burn, quarterly expense growth, and how much of cash and investments remains available for operations.
- Verify progress, enrollment, endpoints, safety, and regulatory feedback for the three registration-directed selinexor trials; distinguish interim response data from confirmatory results.
- Assess dilution and future financing needs, particularly after the July 2014 and January 2015 equity offerings and given continued losses.
- Monitor manufacturing continuity, intellectual-property protection, and the remaining regulatory and commercial requirements for selinexor and verdinexor.